Abstract Purpose of Review Immune checkpoint blockade (ICB) has changed the clinical
course of multiple cancer types and durable responses have now been observed in breast …

Introduction The addition of immune checkpoint inhibitors (ICIs) to frontline chemotherapy
has improved survival for patients with advanced triple-negative breast cancer (TNBC) …

In the recent years characterized by the cancer immunotherapy revolution, attention has
turned to how to potentially boost and/or generate an efficient anti-tumor immune response …

Opinion statement Immune checkpoint blockade (ICB) has revolutionized the treatment
landscape across multiple solid tumor types. In triple-negative breast cancer (TNBC), clinical …

ABSTRACT Introduction Immune checkpoint inhibitors (ICIs) have recently entered into the
therapeutic scenario of metastatic breast cancer. However, only a proportion of patients …

Immunotherapy continues to redefine the solid tumor treatment landscape, with inhibitors of
the PD-L1/PD-1 immune checkpoint having the most widespread impact. As the most …

Immune checkpoint inhibitors have modified the treatment algorithm in a variety of cancer
types, including breast cancer. Nevertheless, optimal selection of ideal candidates to these …

Triple-negative breast cancers (TNBCs) exhibit heightened T cell infiltration, contributing to
an enhanced response to immune checkpoint blockade (ICB) compared with other …

Immune Checkpoint Inhibitors (ICIs) have remarkably modified the way solid tumors are
managed, including breast cancer. Unfortunately, only a relatively small number of breast …

The advent of immunotherapy, particularly immune checkpoint inhibitors (ICIs), has
revolutionized the treatment of solid tumor malignancies. In breast cancer, the most robust …